User profiles for Helen Y. Chu
 | Helen Y ChuProfessor of Medicine, University of Washington Verified email at uw.edu Cited by 23586 |
[HTML][HTML] Remdesivir for the treatment of Covid-19
Background Although several therapeutic agents have been evaluated for the treatment of
coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …
coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …
Remdesivir for the treatment of Covid-19—preliminary report
BACKGROUND: Although several therapeutic agents have been evaluated for the treatment
of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …
of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …
[HTML][HTML] Sequelae in adults at 6 months after COVID-19 infection
… Author Contributions: Ms Logue and Dr Chu had full access to all of the data in the study
and take responsibility for the integrity of the data and the accuracy of the data analysis. Mr …
and take responsibility for the integrity of the data and the accuracy of the data analysis. Mr …
[HTML][HTML] The effects of the COVID-19 pandemic on community respiratory virus activity
EJ Chow, TM Uyeki, HY Chu - Nature Reviews Microbiology, 2023 - nature.com
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
substantial global morbidity and deaths, leading governments to turn to non-pharmaceutical …
substantial global morbidity and deaths, leading governments to turn to non-pharmaceutical …
Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity
INTRODUCTION A systematic characterization of the humoral response to severe acute
respiratory system coronavirus 2 (SARS-CoV-2) epitopes has yet to be performed. This analysis …
respiratory system coronavirus 2 (SARS-CoV-2) epitopes has yet to be performed. This analysis …
[PDF][PDF] Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
The evolution of SARS-CoV-2 could impair recognition of the virus by human antibody-mediated
immunity. To facilitate prospective surveillance for such evolution, we map how …
immunity. To facilitate prospective surveillance for such evolution, we map how …
[HTML][HTML] Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
Antibodies are a principal determinant of immunity for most RNA viruses and have promise
to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 …
to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 …
Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants
…, M Ahlrichs, L Carter, G Snell, MS Pizzuto, HY Chu… - Science, 2021 - science.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission leads to the
emergence of variants, including the B.1.617.2 (Delta) variant of concern that is causing a …
emergence of variants, including the B.1.617.2 (Delta) variant of concern that is causing a …
[HTML][HTML] Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays
SARS-CoV-2 enters cells using its Spike protein, which is also the main target of
neutralizing antibodies. Therefore, assays to measure how antibodies and sera affect Spike-mediated …
neutralizing antibodies. Therefore, assays to measure how antibodies and sera affect Spike-mediated …
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry
distinct spike mutations resulting in escape from antibodies induced by previous infection or …
distinct spike mutations resulting in escape from antibodies induced by previous infection or …